Is ALDX or EVAX more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% Evaxion A/S N/A -73.56% -37.45%

Is EVAX or ONCY more profitable?

Evaxion A/S's return on equity of -73.56% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Oncolytics Biotech N/A -2,185.97% -321.54%

Is PLYX or EVAX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Evaxion A/S N/A -73.56% -37.45%

Do analysts prefer EVAX or AADI?

Evaxion A/S presently has a consensus target price of $11.00, indicating a potential upside of 290.07%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Evaxion A/S is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Evaxion A/S (EVAX) Competitors

$2.82 -0.02 (-0.70%)

Closing price 03:58 PM Eastern

Extended Trading

$2.81 -0.01 (-0.39%)

As of 07:51 PM Eastern

Compare

EVAX vs. ALDX, ONCY, PLYX, VRCA, and AADI

Should you buy Evaxion A/S stock or one of its competitors? MarketBeat compares Evaxion A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evaxion A/S include Aldeyra Therapeutics (ALDX), Oncolytics Biotech (ONCY), Polaryx Therapeutics (PLYX), Verrica Pharmaceuticals (VRCA), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.

How does Evaxion A/S compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Aldeyra Therapeutics' return on equity of -57.34% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Evaxion A/S	N/A	-73.56%	-37.45%

Evaxion A/S has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Evaxion A/S	$7.53M	3.12	-$7.71M	-$1.47	N/A

Aldeyra Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

In the previous week, Aldeyra Therapeutics had 3 more articles in the media than Evaxion A/S. MarketBeat recorded 4 mentions for Aldeyra Therapeutics and 1 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 1.89 beat Aldeyra Therapeutics' score of 1.20 indicating that Evaxion A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
Evaxion A/S	Very Positive

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aldeyra Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 243.75%. Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 290.07%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts plainly believe Evaxion A/S is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Evaxion A/S beats Aldeyra Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Evaxion A/S compare to Oncolytics Biotech?

Evaxion A/S (NASDAQ:EVAX) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Evaxion A/S has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.12	-$7.71M	-$1.47	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Evaxion A/S and Evaxion A/S both had 1 articles in the media. Evaxion A/S's average media sentiment score of 1.89 equaled Oncolytics Biotech'saverage media sentiment score.

Company	Overall Sentiment
Evaxion A/S	Very Positive
Oncolytics Biotech	Very Positive

Evaxion A/S currently has a consensus price target of $11.00, suggesting a potential upside of 290.07%. Oncolytics Biotech has a consensus price target of $8.50, suggesting a potential upside of 1,028.82%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Evaxion A/S has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Evaxion A/S's return on equity of -73.56% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Summary

Evaxion A/S beats Oncolytics Biotech on 8 of the 13 factors compared between the two stocks.

How does Evaxion A/S compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Evaxion A/S (NASDAQ:EVAX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, Polaryx Therapeutics and Polaryx Therapeutics both had 1 articles in the media. Evaxion A/S's average media sentiment score of 1.89 beat Polaryx Therapeutics' score of 1.87 indicating that Evaxion A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Very Positive
Evaxion A/S	Very Positive

11.0% of Evaxion A/S shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Polaryx Therapeutics' return on equity of 0.00% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Evaxion A/S	N/A	-73.56%	-37.45%

Polaryx Therapeutics has higher earnings, but lower revenue than Evaxion A/S. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A
Evaxion A/S	$7.53M	3.12	-$7.71M	-$1.47	N/A

Polaryx Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 295.35%. Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 290.07%. Given Polaryx Therapeutics' higher probable upside, equities research analysts plainly believe Polaryx Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Evaxion A/S beats Polaryx Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Evaxion A/S compare to Verrica Pharmaceuticals?

Evaxion A/S (NASDAQ:EVAX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Evaxion A/S has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

In the previous week, Verrica Pharmaceuticals had 4 more articles in the media than Evaxion A/S. MarketBeat recorded 5 mentions for Verrica Pharmaceuticals and 1 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 1.89 beat Verrica Pharmaceuticals' score of 0.36 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion A/S	Very Positive
Verrica Pharmaceuticals	Neutral

Evaxion A/S currently has a consensus target price of $11.00, indicating a potential upside of 290.07%. Verrica Pharmaceuticals has a consensus target price of $14.50, indicating a potential upside of 175.67%. Given Evaxion A/S's stronger consensus rating and higher probable upside, equities research analysts clearly believe Evaxion A/S is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Evaxion A/S has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.12	-$7.71M	-$1.47	N/A
Verrica Pharmaceuticals	$35.58M	2.54	-$17.89M	-$1.03	N/A

Evaxion A/S has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Evaxion A/S's return on equity of -73.56% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Evaxion A/S beats Verrica Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Evaxion A/S compare to Aadi Bioscience?

Evaxion A/S (NASDAQ:EVAX) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, Evaxion A/S had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 1 mentions for Evaxion A/S and 0 mentions for Aadi Bioscience. Evaxion A/S's average media sentiment score of 1.89 beat Aadi Bioscience's score of 0.00 indicating that Evaxion A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Evaxion A/S	Very Positive
Aadi Bioscience	Neutral

Evaxion A/S has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Evaxion A/S has higher earnings, but lower revenue than Aadi Bioscience. Evaxion A/S is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.12	-$7.71M	-$1.47	N/A
Aadi Bioscience	$25.07M	3.61	-$65.76M	-$2.35	N/A

Evaxion A/S has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Evaxion A/S presently has a consensus target price of $11.00, indicating a potential upside of 290.07%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Evaxion A/S is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Evaxion A/S beats Aadi Bioscience on 10 of the 16 factors compared between the two stocks.

Get Evaxion A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVAX vs. The Competition

Export

Metric	Evaxion A/S	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.69M	$1.75B	$7.05B	$12.03B
Dividend Yield	N/A	N/A	2.65%	10.11%
P/E Ratio	-1.92	73.60	27.67	23.56
Price / Sales	3.12	21.38	526.48	92.53
Price / Cash	N/A	25.57	51.74	58.30
Price / Book	1.38	5.59	10.06	5.85
Net Income	-$7.71M	-$54.76M	$3.60B	$336.53M
7 Day Performance	-7.54%	-0.36%	-0.26%	-0.46%
1 Month Performance	-9.03%	-4.05%	-3.30%	-4.97%
1 Year Performance	1.81%	-4.11%	22.60%	16.73%

Evaxion A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVAX Evaxion A/S	3.4089 of 5 stars	$2.82 -0.7%	$11.00 +290.1%	-3.4%	$23.69M	$7.53M	N/A	60	Positive News
ALDX Aldeyra Therapeutics	3.6706 of 5 stars	$1.58 -0.3%	$5.50 +248.1%	-68.4%	$95.61M	N/A	N/A	10	News Coverage Positive News Upcoming Earnings Short Interest Decrease Gap Up
ONCY Oncolytics Biotech	2.3299 of 5 stars	$0.79 -1.0%	$8.50 +973.1%	-26.3%	$95.50M	N/A	N/A	30	Positive News Upcoming Earnings
PLYX Polaryx Therapeutics	3.9574 of 5 stars	$1.99 +1.5%	$8.50 +327.1%	N/A	$92.18M	N/A	N/A	11	Positive News
VRCA Verrica Pharmaceuticals	2.4588 of 5 stars	$5.40 +0.9%	$14.50 +168.5%	-17.0%	$91.91M	$35.58M	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVAX) was last updated on 7/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evaxion A/S (EVAX) Competitors

EVAX vs. ALDX, ONCY, PLYX, VRCA, and AADI

How does Evaxion A/S compare to Aldeyra Therapeutics?

Summary

How does Evaxion A/S compare to Oncolytics Biotech?

Summary

How does Evaxion A/S compare to Polaryx Therapeutics?

Summary

How does Evaxion A/S compare to Verrica Pharmaceuticals?

Summary

How does Evaxion A/S compare to Aadi Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evaxion A/S (EVAX) Competitors

EVAX vs. ALDX, ONCY, PLYX, VRCA, and AADI

How does Evaxion A/S compare to Aldeyra Therapeutics?

Is ALDX or EVAX more profitable?

Which has higher valuation & earnings, ALDX or EVAX?

Which has more risk and volatility, ALDX or EVAX?

Does the media favor ALDX or EVAX?

Do insiders & institutionals believe in ALDX or EVAX?

Do analysts recommend ALDX or EVAX?

Summary

How does Evaxion A/S compare to Oncolytics Biotech?

Which has preferable valuation & earnings, EVAX or ONCY?

Do institutionals & insiders hold more shares of EVAX or ONCY?

Does the media favor EVAX or ONCY?

Do analysts prefer EVAX or ONCY?

Which has more risk & volatility, EVAX or ONCY?

Is EVAX or ONCY more profitable?

Summary

How does Evaxion A/S compare to Polaryx Therapeutics?

Does the media refer more to PLYX or EVAX?

Do institutionals and insiders believe in PLYX or EVAX?

Is PLYX or EVAX more profitable?

Which has stronger valuation and earnings, PLYX or EVAX?

Do analysts rate PLYX or EVAX?

Summary

How does Evaxion A/S compare to Verrica Pharmaceuticals?

Which has more risk and volatility, EVAX or VRCA?

Does the media refer more to EVAX or VRCA?

Do analysts prefer EVAX or VRCA?

Which has stronger earnings & valuation, EVAX or VRCA?

Is EVAX or VRCA more profitable?

Do insiders and institutionals believe in EVAX or VRCA?

Summary

How does Evaxion A/S compare to Aadi Bioscience?

Does the media favor EVAX or AADI?

Which has more risk and volatility, EVAX or AADI?

Do insiders & institutionals have more ownership in EVAX or AADI?

Which has higher valuation and earnings, EVAX or AADI?

Is EVAX or AADI more profitable?

Do analysts prefer EVAX or AADI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools